Table 1.
Baseline characteristics of patients with organophosphate poisoning, stratified according to diabetes mellitus status (N = 118)
| Variable | Total (N = 118) | Non-diabetes mellitus (N = 109) | Diabetes mellitus (N = 9) | P |
|---|---|---|---|---|
| Age, years (mean ± SD) |
53.45 ± 16.20 |
52.32 ± 16.04 |
67.11 ± 11.84 |
0.008** |
| Male, n (%) |
77 (65.3) |
73 (67.0) |
4 (44.4) |
0.173 |
| Organophosphate type, n (%): |
|
|
|
0.082 |
| Chlorpyrifos |
48 (40.7) |
44 (40.4) |
4 (44.4) |
|
| Profenofos |
16 (13.6) |
16 (14.7) |
0 (0.0) |
|
| Methamidophos |
14 (11.9) |
14 (12.8) |
0 (0.0) |
|
| Mevinphos |
10 (8.5) |
9 (8.3) |
1 (11.1) |
|
| Dimethoate |
9 (7.6) |
8 (7.3) |
1 (11.1) |
|
| Malathion |
6 (5.1) |
5 (4.6) |
1 (11.1) |
|
| Parathion |
4 (3.4) |
4 (3.7) |
0 (0.0) |
|
| Acephate |
3 (2.5) |
2 (1.8) |
1 (11.1) |
|
| Trichlorfon |
3 (2.5) |
3 (2.8) |
0 (0.0) |
|
| Terbufos |
2 (1.7) |
2 (1.8) |
0 (0.0) |
|
| Dichlorvos |
1 (0.8) |
1 (0.9) |
0 (0.0) |
|
| Fenamiphos |
1 (0.8) |
1 (0.9) |
0 (0.0) |
|
| Phorate |
1 (0.8) |
0 (0.0) |
1 (11.1) |
|
| Organophosphate toxicity, n (%): |
|
|
|
0.206 |
| Ia, extremely hazardous |
17 (14.4) |
15 (13.8) |
2 (22.2) |
|
| Ib, highly hazardous |
16 (13.6) |
16 (14.7) |
0 (0.0) |
|
| II, moderately hazardous |
76 (64.4) |
71 (65.1) |
5 (55.6) |
|
| III, slightly hazardous |
9 (7.6) |
7 (6.4) |
2 (22.2) |
|
| U, unlikely to present acute hazard |
0 (0) |
0 (0) |
0 (0) |
|
| Hypertension, n (%) |
21 (17.8) |
18 (16.5) |
3 (33.3) |
0.199 |
| Old stroke, n (%) |
10 (8.5) |
8 (7.3) |
2 (22.2) |
0.123 |
| Coronary artery disease, n (%) |
3 (2.5) |
3 (2.8) |
0 (0.0) |
0.614 |
| Structural heart disease, n (%) |
11 (9.3) |
10 (9.2) |
1 (11.1) |
0.848 |
| Chronic obstructive pulmonary disease, n (%) |
9 (7.6) |
8 (7.3) |
1 (11.1) |
0.682 |
| Malignancy, n (%) |
3 (2.5) |
3 (2.8) |
0 (0.0) |
0.614 |
| Mental disorder, n (%) |
51 (43.2) |
46 (42.2) |
5 (55.6) |
0.437 |
| Smoking habit, n (%) |
52 (44.1) |
50 (45.9) |
2 (22.2) |
0.170 |
| Alcohol consumption, n (%) |
49 (41.5) |
47 (43.1) |
2 (22.2) |
0.221 |
| Use of medications that might be associated with QTc 7prolongation, n (%): |
|
|
|
|
| Antiarrhythmic agents |
20 (16.9) |
17 (15.6) |
3 (33.3) |
0.173 |
| Antipsychotics and antidepressants |
30 (25.4) |
27 (24.8) |
3 (33.3) |
0.571 |
| Antimicrobials | 10 (8.5) | 9 (8.3) | 1 (11.1) | 0.768 |
QTc, corrected QT interval.
Note: **P < 0.01.